Tokyo Trading Reko Deq at Chughtai Lab

Tokyo Trading Reko Deq at Chughtai Lab

The Tokyo Trading Reko Deq is a highly advanced, multi-panel rapid urine drug screening system designed to detect the presence of multiple illicit substances and prescription medications simultaneously. Utilizing state-of-the-art lateral flow chromatographic immunoassay technology, this diagnostic test provides rapid, qualitative results by identifying specific drug metabolites in human urine. At Chughtai Lab, Pakistan’s premier diagnostic network, the Tokyo Trading Reko Deq test is conducted under strict quality control protocols to ensure maximum clinical accuracy, reliability, and confidentiality. The test is of paramount clinical importance in occupational health, forensic medicine, addiction treatment monitoring, and emergency toxicology, offering a rapid and non-invasive method to screen for substance use.

The underlying technology of the Tokyo Trading Reko Deq relies on the principle of competitive binding. The test card or cup contains chromatographic strips pre-coated with drug-protein conjugates. During testing, a urine specimen migrates upward via capillary action. If a drug or its metabolite is present in the urine below its specific cut-off concentration, it will not saturate the binding sites of the specific antibodies pre-coated on the strip. The antibodies will then react with the drug-protein conjugate, and a visible colored line will appear in the test line region of the specific drug strip. Conversely, if the drug concentration is above the cut-off level, it saturates all the antibody binding sites, preventing the attachment of the antibody to the conjugate, resulting in the absence of a colored line. This competitive immunoassay design ensures rapid, visual, and highly sensitive screening for multiple drug classes within minutes.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the integrity of the urine specimen and the accuracy of the Tokyo Trading Reko Deq test, patients must adhere to specific preparation guidelines:

• Medication Disclosure: Patients must provide a comprehensive list of all prescription medications, over-the-counter drugs, herbal remedies, and dietary supplements taken within the last 14 days. Certain medications, such as fluoroquinolones, proton pump inhibitors, and decongestants, can cross-react with the immunoassay antibodies, potentially causing false-positive results.
• Fluid Intake Regulation: Patients should avoid consuming excessive amounts of water or other fluids in the 2 to 4 hours prior to sample collection. Overhydration can dilute the urine specimen, lowering the concentration of drug metabolites below the detection threshold and reducing the specific gravity and creatinine levels, which may render the sample invalid.
• Dietary Restrictions: Avoid consuming foods containing poppy seeds for at least 48 hours before the test, as poppy seeds contain trace amounts of morphine and codeine that can trigger a positive result for opiates.
• Identification and Documentation: Bring a valid government-issued photo identification card (such as a CNIC) to the Chughtai Lab collection center, especially if the test is required for official, legal, or pre-employment purposes.

During the Procedure

The collection process for the Tokyo Trading Reko Deq test at Chughtai Lab follows a standardized, secure, and hygienic protocol to prevent sample substitution, dilution, or adulteration:

• Secure Collection Environment: The patient is directed to a designated restroom where potential sources of adulteration (such as running water, soap, or chemical agents) are secured or restricted. Blue coloring agents may be added to the toilet bowl water to prevent dilution.
• Specimen Collection: The patient is provided with a sterile, single-use, tamper-evident collection cup. A minimum of 30 to 45 milliliters of fresh urine must be voided into the cup.
• Temperature Verification: Immediately upon receiving the specimen, the laboratory technician checks the built-in temperature strip on the collection cup. The temperature must read between 32°C and 38°C (90°F to 100°F) within four minutes of voiding. A temperature outside this range strongly suggests sample substitution or tampering.
• Adulteration Testing: The Tokyo Trading Reko Deq panel often includes built-in chemically treated pads to assess specimen validity by measuring pH, specific gravity, and the presence of oxidants (such as bleach or glutaraldehyde).
• Chain of Custody: For legal or occupational testing, a strict chain of custody form is completed, signed by both the patient and the collector, and the specimen is sealed with tamper-evident tape.

When is a Tokyo Trading Reko Deq Performed?

Workplace and Pre-Employment Screening

Many corporate organizations, safety-sensitive industries, and government institutions in Pakistan utilize the Tokyo Trading Reko Deq at Chughtai Lab to conduct pre-employment and random drug screenings. This is crucial for maintaining workplace safety, reducing occupational hazards, and ensuring that employees operating heavy machinery, driving commercial vehicles, or working in high-risk environments are not under the influence of cognitive-impairing substances.

Addiction Treatment and Rehabilitation Monitoring

Psychiatrists, addiction specialists, and rehabilitation centers rely on this multi-drug panel to monitor treatment compliance in patients undergoing therapy for substance use disorders. Regular, often unannounced, urine drug screening helps clinicians verify abstinence, detect early relapses, and adjust therapeutic interventions accordingly, fostering a supportive and accountable recovery process.

Forensic and Legal Determinations

The Tokyo Trading Reko Deq is frequently requested by legal authorities, courts, and law enforcement agencies for forensic evaluations. It is utilized in child custody disputes, probation compliance monitoring, and accident investigations where drug impairment is suspected. The highly structured collection process at Chughtai Lab ensures that the findings are legally defensible.

Emergency Psychiatric and Medical Assessment

In emergency departments and psychiatric clinics, patients presenting with acute psychosis, altered mental status, unexplained seizures, or suspected drug overdose require rapid diagnostic evaluation. The Tokyo Trading Reko Deq provides emergency physicians with rapid, preliminary results within minutes, enabling them to make critical, life-saving treatment decisions and differentiate drug-induced symptoms from primary psychiatric disorders.

Pain Management Compliance

Physicians prescribing long-term controlled substances, such as opioids or benzodiazepines for chronic pain management, utilize urine drug screening to ensure patients are taking their medications as prescribed. The test helps detect potential diversion (where the prescribed drug is absent from the urine) or the concurrent use of non-prescribed, illicit substances, which could lead to dangerous drug interactions.

What Does a Tokyo Trading Reko Deq Detect?

The Tokyo Trading Reko Deq multi-drug panel is capable of detecting a wide array of substances, metabolites, and specimen validity parameters. The specific findings and parameters evaluated include:

• Tetrahydrocannabinol (THC): Detects marijuana metabolites (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid) with a standard cut-off of 50 ng/mL.
• Opiates (OPI/MOP): Identifies heroin, morphine, and codeine metabolites, typically utilizing a cut-off of 300 ng/mL or 2000 ng/mL to minimize false positives from dietary sources.
• Cocaine (COC): Detects benzoylecgonine, the primary metabolite of cocaine, with a cut-off of 300 ng/mL.
• Amphetamine (AMP): Identifies central nervous system stimulants like amphetamine with a cut-off of 1000 ng/mL.
• Methamphetamine (MET/mAMP): Specifically detects methamphetamine, a highly addictive stimulant, with a cut-off of 1000 ng/mL.
• Benzodiazepines (BZO): Detects widely prescribed anxiolytics and sedatives, such as diazepam, alprazolam, and oxazepam, with a cut-off of 300 ng/mL.
• Barbiturates (BAR): Identifies sedative-hypnotic medications like phenobarbital and secobarbital with a cut-off of 300 ng/mL.
• Methadone (MTD): Detects methadone, a synthetic opioid used for pain management and opioid addiction treatment, with a cut-off of 300 ng/mL.
• Phencyclidine (PCP): Identifies the hallucinogen phencyclidine with a cut-off of 25 ng/mL.
• Methylenedioxymethamphetamine (MDMA): Detects ecstasy or MDMA with a cut-off of 500 ng/mL.
• Tricyclic Antidepressants (TCA): Screens for older generation antidepressants like amitriptyline and imipramine with a cut-off of 1000 ng/mL.
• Buprenorphine (BUP): Detects buprenorphine, used in opioid replacement therapy, with a cut-off of 10 ng/mL.
• Oxycodone (OXY): Identifies the semi-synthetic opioid oxycodone with a cut-off of 100 ng/mL.
• Propoxyphene (PPX): Detects propoxyphene, a narcotic analgesic, with a cut-off of 300 ng/mL.
• Urine Creatinine: Evaluates specimen dilution; levels below 20 mg/dL suggest an abnormally diluted sample.
• Specific Gravity: Measures urine concentration; values outside the range of 1.002 to 1.030 indicate potential dilution or adulteration.
• pH Levels: Assesses the acidity or alkalinity of the sample; normal urine pH ranges from 4.5 to 8.0, and values outside this range suggest chemical manipulation.
• Oxidants/Bleach: Detects the presence of exogenous oxidizing agents added to oxidize and destroy drug metabolites.
• Glutaraldehyde: Identifies the presence of exogenous adulterants designed to interfere with the immunoassay enzymes.
• Pyridinium Chlorochromate: Detects chemical adulterants used to mask the presence of THC and other drugs.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is renowned for its rapid turnaround times and highly efficient reporting systems. Because the Tokyo Trading Reko Deq is a rapid lateral flow test, preliminary screening results are typically completed within a few hours of sample collection. Once verified by a consultant pathologist, the official report is uploaded to Chughtai Lab’s secure online portal. Patients and referring physicians can access reports instantly via the Chughtai Lab mobile application, official website, or through automated WhatsApp alerts. Physical copies of the report can also be collected from any Chughtai Lab diagnostic center across Pakistan. In cases where a screening result is presumptively positive, Chughtai Lab offers confirmatory testing using advanced chromatography techniques upon clinical request.

Tokyo Trading Reko Deq Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Tetrahydrocannabinol (THC)	Negative (Below 50 ng/mL)	Positive (Above 50 ng/mL; indicates recent cannabis use)
Opiates (OPI/MOP)	Negative (Below 2000 ng/mL)	Positive (Above 2000 ng/mL; indicates morphine, codeine, or heroin use)
Benzodiazepines (BZO)	Negative (Below 300 ng/mL)	Positive (Above 300 ng/mL; indicates benzodiazepine use)
Cocaine (COC)	Negative (Below 300 ng/mL)	Positive (Above 300 ng/mL; indicates recent cocaine use)
Amphetamines (AMP)	Negative (Below 1000 ng/mL)	Positive (Above 1000 ng/mL; indicates amphetamine use)
Urine Creatinine	20 to 350 mg/dL	Below 20 mg/dL (Indicates a diluted or substituted specimen)
Specific Gravity	1.002 to 1.030	Outside 1.002 – 1.030 (Indicates specimen dilution or chemical addition)
pH Level	4.5 to 8.0	Below 4.5 or Above 8.0 (Indicates potential chemical adulteration)
Oxidants / Adulterants	Negative	Positive (Presence of bleach, glutaraldehyde, or other masking agents)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Tokyo Trading Reko Deq?

• ISO 15189 Certified Laboratories: Chughtai Lab adheres to international standards of quality, ensuring the highest level of accuracy and precision in pathology testing.
• Experienced Pathologists and Toxicologists: All drug screening and toxicology reports are supervised and verified by highly qualified consultant pathologists.
• Strict Chain of Custody Protocols: Chughtai Lab implements rigorous, tamper-evident collection and processing procedures to ensure legally defensible results.
• Advanced Adulteration Detection: The laboratory utilizes multi-parameter testing to identify specimen dilution, substitution, or chemical masking agents.
• Confidential and Secure Reporting: Patient privacy is paramount; Chughtai Lab ensures that drug screening results are shared only with authorized individuals.
• Convenient Online and Mobile App Access: Patients can view, download, and share their diagnostic reports seamlessly via the Chughtai Lab portal and mobile application.
• Extensive Nationwide Network: With hundreds of collection centers across Pakistan, patients can easily access professional testing services close to home.
• Home Sample Collection Services: Chughtai Lab offers professional, secure home sample collection services, bringing high-quality diagnostics directly to your doorstep.